Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients

Summary

This study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in moderate to severe refractory ulcerative colitis (UC) patients followed by a maximum of 12-week open-label efficacy and safety study in responders.

Timeline

Start

2006-09

Primary completion

2008-04

Completion

2008-04

Drugs

Indications